Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.
Gutwillig A, Santana-Magal N, Farhat-Younis L, Rasoulouniriana D, Madi A, Luxenburg C, Cohen J, Padmanabhan K, Shomron N, Shapira G, Gleiberman A, Parikh R, Levy C, Feinmesser M, Hershkovitz D, Zemser-Werner V, Zlotnik O, Kroon S, Hardt WD, Debets R, Reticker-Flynn NE, Rider P, Carmi Y.
Gutwillig A, et al. Among authors: carmi y.
Elife. 2022 Sep 20;11:e80315. doi: 10.7554/eLife.80315.
Elife. 2022.
PMID: 36124553
Free PMC article.